应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
VKTX Viking Therapeutics, Inc.
耶稣受难日休市 03-28 16:00:00 EDT
82.00
-1.34
-1.61%
盘后
81.60
-0.40
-0.49%
19:59 EDT
最高
84.70
最低
80.50
成交量
433.14万
今开
83.50
昨收
83.34
日振幅
5.04%
总市值
88.57亿
流通市值
88.57亿
总股本
1.08亿
成交额
3.57亿
换手率
4.01%
流通股本
1.08亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
减肥药试验成功潜力巨大!这只小盘股有望起飞
金十数据 · 15:43
减肥药试验成功潜力巨大!这只小盘股有望起飞
Viking Therapeutics, Inc.盘中异动 早盘急速拉升5.01%报84.88美元
自选股智能写手 · 03-27 21:33
Viking Therapeutics, Inc.盘中异动 早盘急速拉升5.01%报84.88美元
港股概念追踪 |Viking(VKTX.US)创新口服减肥疗法临床结果积极 减肥药受关注(附概念股)
智通财经 · 03-27 10:42
港股概念追踪 |Viking(VKTX.US)创新口服减肥疗法临床结果积极 减肥药受关注(附概念股)
4周体重下降近10斤!Viking(VKTX.US)创新口服减肥疗法临床结果积极
智通财经 · 03-27 08:48
4周体重下降近10斤!Viking(VKTX.US)创新口服减肥疗法临床结果积极
昨夜今晨 | 官宣利好,“减肥药新贵”Viking飙升近17%;英伟达尾盘跳水,特斯拉逆市涨近3%
老虎资讯综合 · 03-27 07:34
昨夜今晨 | 官宣利好,“减肥药新贵”Viking飙升近17%;英伟达尾盘跳水,特斯拉逆市涨近3%
Viking Therapeutics(VKTX)涨26% VK2735肥胖药早期研究报积极结果
金吾财讯 · 03-26 23:40
Viking Therapeutics(VKTX)涨26% VK2735肥胖药早期研究报积极结果
Viking Therapeutics, Inc.股价上涨16.77% 市值涨14.62亿美元
自选股智能写手 · 03-26 21:31
Viking Therapeutics, Inc.股价上涨16.77% 市值涨14.62亿美元
“减肥药新贵”Viking的口服减肥药最新试验结果积极
智通财经 · 03-26 21:10
“减肥药新贵”Viking的口服减肥药最新试验结果积极
Viking Therapeutics盘前大涨超21% 报告肥胖药早期研究的积极结果
金融界 · 03-26 20:55
Viking Therapeutics盘前大涨超21% 报告肥胖药早期研究的积极结果
BUZZ-维京药物在早期试验中被证明可减轻体重;股价上涨
Reuters · 03-26
BUZZ-维京药物在早期试验中被证明可减轻体重;股价上涨
更新版 1-Viking Therapeutics 的实验性药片在小型研究中有助于减轻体重
Reuters · 03-26
更新版 1-Viking Therapeutics 的实验性药片在小型研究中有助于减轻体重
Viking Therapeutics 公司称其实验性药片在早期研究中减轻了体重
Reuters · 03-26
Viking Therapeutics 公司称其实验性药片在早期研究中减轻了体重
Viking Therapeutics, Inc.盘中异动 急速拉升5.06%
自选股智能写手 · 03-25
Viking Therapeutics, Inc.盘中异动 急速拉升5.06%
Viking Therapeutics, Inc.盘中异动 股价大涨5.02%
自选股智能写手 · 03-19
Viking Therapeutics, Inc.盘中异动 股价大涨5.02%
BUZZ-Madrigal公司脂肪肝药物获美国食品及药物管理局批准,业绩大增
Reuters · 03-15
BUZZ-Madrigal公司脂肪肝药物获美国食品及药物管理局批准,业绩大增
资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH,竞争对手却围追堵截
Reuters · 03-15
资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH,竞争对手却围追堵截
Viking Therapeutics, Inc.盘中异动 快速下跌5.14%报68.26美元
自选股智能写手 · 03-14
Viking Therapeutics, Inc.盘中异动 快速下跌5.14%报68.26美元
Viking Therapeutics, Inc.盘中异动 大幅上涨5.01%报66.62美元
自选股智能写手 · 03-13
Viking Therapeutics, Inc.盘中异动 大幅上涨5.01%报66.62美元
Viking Therapeutics, Inc.盘中异动 股价大跌5.22%
自选股智能写手 · 03-11
Viking Therapeutics, Inc.盘中异动 股价大跌5.22%
Viking Therapeutics, Inc.盘中异动 早盘大幅下挫5.00%报70.30美元
自选股智能写手 · 03-08
Viking Therapeutics, Inc.盘中异动 早盘大幅下挫5.00%报70.30美元
加载更多
公司概况
公司名称:
Viking Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司,致力于开发新的,第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612,它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物,它在同药物中排列第一。公司的第二临床程序vk5211,可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂,或SARM。
发行价格:
--
{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":82,"timestamp":1711656000000,"preClose":83.34,"halted":0,"volume":4331410,"hourTrading":{"tag":"盘后","latestPrice":81.6,"preClose":82,"latestTime":"19:59 EDT","volume":102438,"amount":8398366.1579,"timestamp":1711670358405},"delay":0,"floatShares":108011073,"shares":108011073,"eps":-0.910415,"marketStatus":"耶稣受难日休市","marketStatusCode":7,"change":-1.34,"latestTime":"03-28 16:00:00 EDT","open":83.5,"high":84.7,"low":80.5,"amount":356987578.7453,"amplitude":0.050396,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.910415,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1711958400000},"adr":0,"listingDate":1430280000000,"adjPreClose":83.34,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":83.63,"preClose":83.34,"latestTime":"09:29 EDT","volume":28208,"amount":2346928.44848,"timestamp":1711632547763},"postHourTrading":{"tag":"盘后","latestPrice":81.6,"preClose":82,"latestTime":"19:59 EDT","volume":102438,"amount":8398366.1579,"timestamp":1711670358405},"volumeRatio":0.6261782795032471},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"2423439733","title":"减肥药试验成功潜力巨大!这只小盘股有望起飞","url":"https://stock-news.laohu8.com/highlight/detail?id=2423439733","media":"金十数据","top":-1,"share":"https://www.laohu8.com/m/news/2423439733?lang=zh_cn&edition=full","pubTime":"2024-03-29 15:43","pubTimestamp":1711698214,"startTime":"0","endTime":"0","summary":"TERN是一家备受关注的小盘股公司,他们正在进行一项引人瞩目的肥胖症治疗药物试验。","market":"hk","thumbnail":"https://cdn-news.jin10.com/c40c0b04-c780-4fae-8a17-73b8cb5cb986.png/lite","type":0,"news_type":0,"thumbnails":["https://cdn-news.jin10.com/c40c0b04-c780-4fae-8a17-73b8cb5cb986.png/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=135429&type=news&data_type=0","is_publish_highlight":false,"gpt_icon":0},{"id":"2422751997","title":"Viking Therapeutics, Inc.盘中异动 早盘急速拉升5.01%报84.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422751997","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422751997?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:33","pubTimestamp":1711546404,"startTime":"0","endTime":"0","summary":"北京时间2024年03月27日21时33分,Viking Therapeutics, Inc.股票出现异动,股价快速上涨5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.30%。其相关个股中,Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 涨幅较大,Ibio, Inc.、Lixte Biotechnology Holdings, Inc.、Hoth Therapeutics, Inc.较为活跃,换手率分别为951.03%、445.08%、50.05%,振幅较大的相关个股有Ibio, Inc.、Apollomics Inc C/Wts 01/04/2028 、Lixte Biotechnology Holdings, Inc.,振幅分别为41.74%、27.59%、25.94%。Viking Therapeutics, Inc.公司简介:Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327213325861e1acd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327213325861e1acd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422987585","title":"港股概念追踪 |Viking(VKTX.US)创新口服减肥疗法临床结果积极 减肥药受关注(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422987585","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422987585?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:42","pubTimestamp":1711507367,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月26日,Viking Therapeutics公司宣布,该公司的口服疗法VK2735在治疗肥胖症的1期临床试验中获得积极结果,接受最高剂量治疗的参与者在28天后体重减少5.3%。根据弗若斯特沙利文的报告,全球减肥药物市场规模从2016 年的18亿美元增长到2020年的26亿美元,年复合增长率为9.0%。值得一提是,目前体重管理适应症的相关药物在国内尚未批准上市,联邦制药是国内首家获得该生物类似物临床批件的企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032712273387ba9fb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032712273387ba9fb0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422603210","title":"4周体重下降近10斤!Viking(VKTX.US)创新口服减肥疗法临床结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2422603210","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422603210?lang=zh_cn&edition=full","pubTime":"2024-03-27 08:48","pubTimestamp":1711500536,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月26日,Viking Therapeutics公司宣布,该公司的口服疗法VK2735在治疗肥胖症的1期临床试验中获得积极结果,接受最高剂量治疗的参与者在28天后体重减少5.3%。这项为期28天的剂量递增研究结果突显了口服VK2735治疗的积极临床活性。口服VK2735显示出良好的安全性和耐受性。Viking还计划在2024年下半年,针对肥胖患者启动口服VK2735的2期试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093079.html","is_publish_highlight":false,"gpt_icon":0},{"id":"1110387722","title":"昨夜今晨 | 官宣利好,“减肥药新贵”Viking飙升近17%;英伟达尾盘跳水,特斯拉逆市涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110387722","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1110387722?lang=zh_cn&edition=full","pubTime":"2024-03-27 07:34","pubTimestamp":1711496082,"startTime":"0","endTime":"0","summary":"“减肥药新贵”Viking飙涨逾17%隔夜美股三大股指尾盘跳水,截至收盘,标普500跌0.28%,报5203.58点;纳斯达克指数跌0.42%,报16315.7点;道琼斯工业指数跌0.08%,报39282.33点。超级科技巨头多数走弱,英伟达冲高乏力尾盘跳水跌超2%,META跌超1%,苹果、微软、亚马逊微跌,特斯拉逆市涨近3%。截至发稿,特斯拉的全自动驾驶功能售价为12000美元。叠加商讨意大利建厂的消息影响,特斯拉周二一度涨超6%,收盘时涨幅","market":"us","thumbnail":"https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2422643190","title":"Viking Therapeutics(VKTX)涨26% VK2735肥胖药早期研究报积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2422643190","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2422643190?lang=zh_cn&edition=full","pubTime":"2024-03-26 23:40","pubTimestamp":1711467601,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物制药公司Viking Therapeutics(VKTX)股价抽升,截至发稿,涨26%,报87.13美元。公司报告了对其拟议的VK2735肥胖药物口服制剂的早期研究的积极结果。VK2735口服制剂的1期研究显示,经安慰剂调整后的28天后平均体重减轻3.3%,并补充说,该药物安全且耐受性良好,与胃肠道相关的不良事件发生率低。与目前火爆全球的GLP-1药物类似但又不同的是,VK2735不仅针对胰高血糖素样肽1(GLP-1),同样还针对葡萄糖依赖性胰岛素促泌肽(GIP)受体,是一种双重激动剂。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/ZTViYmJjYTk5MWJmNjYzNjE2ODI2MDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTViYmJjYTk5MWJmNjYzNjE2ODI2MDU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"274346","is_publish_highlight":false,"gpt_icon":0},{"id":"2422613198","title":"Viking Therapeutics, Inc.股价上涨16.77% 市值涨14.62亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422613198","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422613198?lang=zh_cn&edition=full","pubTime":"2024-03-26 21:31","pubTimestamp":1711459909,"startTime":"0","endTime":"0","summary":"北京时间2024年03月26日21时31分,Viking Therapeutics, Inc.股票出现波动,股价急速拉升16.77%。Viking Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.41%。Viking Therapeutics, Inc.公司简介:Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403262131498b65772d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403262131498b65772d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422492618","title":"“减肥药新贵”Viking的口服减肥药最新试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2422492618","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422492618?lang=zh_cn&edition=full","pubTime":"2024-03-26 21:10","pubTimestamp":1711458642,"startTime":"0","endTime":"0","summary":"到2030年,全球抗肥胖药物市场的年销售额可能会增长到1000亿美元左右。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1092768.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422461888","title":"Viking Therapeutics盘前大涨超21% 报告肥胖药早期研究的积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2422461888","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422461888?lang=zh_cn&edition=full","pubTime":"2024-03-26 20:55","pubTimestamp":1711457744,"startTime":"0","endTime":"0","summary":"处于临床阶段的生物制药公司viking therapeutics盘前一度大涨超21%,报83.8美元。消息面上,该公司报告了对其拟议的VK2735肥胖药物口服制剂的早期研究的积极结果。VK2735口服制剂的1期研究显示,经安慰剂调整后的28天后平均体重减轻3.3%,并补充说,该药物安全且耐受性良好,与胃肠道相关的不良事件发生率低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032621054787b7b333&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032621054787b7b333&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422669308","title":"BUZZ-维京药物在早期试验中被证明可减轻体重;股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2422669308","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422669308?lang=zh_cn&edition=full","pubTime":"2024-03-26 19:21","pubTimestamp":1711452079,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 3月26日 - ** Viking Therapeutics 股价盘前上涨约11.3%至77美元** 该公司称 (link) 其药物 VK2735 在早期试验中显示,与安慰剂相比,平均体重减轻达 3.3** 公司计划根据早期数据,在今年晚些时候启动一项中期试验** 截至上次收盘,公司股价在过去 12 个月中上涨了七倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422951736","title":"更新版 1-Viking Therapeutics 的实验性药片在小型研究中有助于减轻体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2422951736","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422951736?lang=zh_cn&edition=full","pubTime":"2024-03-26 19:18","pubTimestamp":1711451928,"startTime":"0","endTime":"0","summary":" 路透社3月26日 - Viking Therapeutics 周二表示,其实验性药片有助于减轻体重,而且在早期研究中被证明是安全的,这使该公司股价在盘前交易中上涨了10%。该公司表示,根据早期研究数据,计划在今年晚些时候启动第二阶段试验。Viking Therapeutics 公司称,该研究观察到,在 28 天内,7 名患者的平均体重减轻了 3.3%,如果与安慰剂比例进行调整的话。该公司上个月报告了一项中期研究的数据,其实验性注射药物VK2735帮助肥胖症患者平均减轻了近15%的体重。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422841693","title":"Viking Therapeutics 公司称其实验性药片在早期研究中减轻了体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2422841693","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422841693?lang=zh_cn&edition=full","pubTime":"2024-03-26 19:09","pubTimestamp":1711451359,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社3月26日 - Viking Therapeutics 周二称,在一项早期试验中,该公司的实验性片剂有助于减轻患者的体重,而且在研究中被证明是安全有效的。该公司表示,计划根据早期数据在今年晚些时候启动第二阶段试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422487715","title":"Viking Therapeutics, Inc.盘中异动 急速拉升5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422487715","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422487715?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:52","pubTimestamp":1711374736,"startTime":"0","endTime":"0","summary":"北京时间2024年03月25日21时52分,Viking Therapeutics, Inc.股票出现波动,股价急速拉升5.06%。Viking Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.07%。其相关个股中,Landos Biopharma, Inc.、Xtl生物制药、Altamira Therapeutics Ltd.涨幅较大,Altamira Therapeutics Ltd.、Xtl生物制药、Salarius Pharmaceuticals, Inc.较为活跃,换手率分别为1869.98%、72.66%、57.49%,振幅较大的相关个股有Xtl生物制药、Altamira Therapeutics Ltd.、Brainstorm Cell Therapeutics Inc.,振幅分别为71.37%、45.67%、26.61%。Viking Therapeutics, Inc.公司简介:Viking Therapeutics Inc 是一家医疗保健服务提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325215216861e0e00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325215216861e0e00&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420743832","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420743832","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420743832?lang=zh_cn&edition=full","pubTime":"2024-03-19 23:32","pubTimestamp":1710862327,"startTime":"0","endTime":"0","summary":"北京时间2024年03月19日23时32分,Viking Therapeutics, Inc.股票出现波动,股价急速上涨5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.12%。其相关个股中,Fusion Pharmaceuticals Inc.、Moolec Science Sa C/Wts 、180 Life Sciences Corp C/Wts 07/11/2025涨幅较大,Enveric Biosciences, Inc.、Hoth Therapeutics, Inc.、Scisparc Ltd.较为活跃,换手率分别为868.85%、417.97%、295.39%,振幅较大的相关个股有Enveric Biosciences, Inc.、Scisparc Ltd.、知临集团,振幅分别为67.27%、52.67%、49.87%。Viking Therapeutics, Inc.公司简介:Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403192332077a4db79d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403192332077a4db79d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419239099","title":"BUZZ-Madrigal公司脂肪肝药物获美国食品及药物管理局批准,业绩大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2419239099","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419239099?lang=zh_cn&edition=full","pubTime":"2024-03-15 17:59","pubTimestamp":1710496767,"startTime":"0","endTime":"0","summary":" 3月15日 - ** 药物开发商Madrigal Pharmaceuticals 股价盘前上涨23.7%至301.20美元** 美国食品和药物管理局周四晚些时候批准了 co 公司治疗脂肪肝的药物,使其成为首个获得批准的脂肪肝治疗药物。** MDGL的口服药物将从4月起以Rezdiffra的品牌名称上市。** 该公司已将这种药物的年批发价定为47,400美元** 在Rezdiffra获批后,Viking Therapeutics 的股价盘前上涨约3.6%至67.38美元。** 截至上次收盘,MDGL 在过去 12 个月中上涨了 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419124937","title":"资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH,竞争对手却围追堵截","url":"https://stock-news.laohu8.com/highlight/detail?id=2419124937","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419124937?lang=zh_cn&edition=full","pubTime":"2024-03-15 04:09","pubTimestamp":1710446976,"startTime":"0","endTime":"0","summary":" 路透社3月14日 - Madrigal Pharmaceuticals公司的 药物成为第一个获得监管部门批准的 ,用于治疗一种以前被称为非酒精性脂肪性肝炎的严重类型的脂肪肝,因为开发一个数十亿美元市场的竞争正在加剧。在周四获得批准之前,该公司在开发这种疾病的治疗方法方面取得了有限的成功,这种疾病与肥胖密切相关,而且正在迅速蔓延。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419602772","title":"Viking Therapeutics, Inc.盘中异动 快速下跌5.14%报68.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419602772","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419602772?lang=zh_cn&edition=full","pubTime":"2024-03-14 21:35","pubTimestamp":1710423330,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日21时35分,Viking Therapeutics, Inc.股票出现异动,股价大幅跳水5.14%。Viking Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.47%。Viking Therapeutics, Inc.公司简介:Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240314213530791a7baa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240314213530791a7baa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419618715","title":"Viking Therapeutics, Inc.盘中异动 大幅上涨5.01%报66.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419618715","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419618715?lang=zh_cn&edition=full","pubTime":"2024-03-13 02:32","pubTimestamp":1710268368,"startTime":"0","endTime":"0","summary":"北京时间2024年03月13日02时32分,Viking Therapeutics, Inc.股票出现波动,股价急速上涨5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.09%。Viking Therapeutics, Inc.公司简介:Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313023248861dd917&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313023248861dd917&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418350912","title":"Viking Therapeutics, Inc.盘中异动 股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2418350912","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418350912?lang=zh_cn&edition=full","pubTime":"2024-03-11 21:33","pubTimestamp":1710164032,"startTime":"0","endTime":"0","summary":"北京时间2024年03月11日21时33分,Viking Therapeutics, Inc.股票出现异动,股价急速下挫5.22%。Viking Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.44%。Viking Therapeutics, Inc.公司简介:Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403112133527919595b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403112133527919595b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417065896","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅下挫5.00%报70.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417065896","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417065896?lang=zh_cn&edition=full","pubTime":"2024-03-08 23:24","pubTimestamp":1709911473,"startTime":"0","endTime":"0","summary":"北京时间2024年03月08日23时24分,Viking Therapeutics, Inc.股票出现波动,股价快速下跌5.00%。Viking Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.51%。Viking Therapeutics, Inc.公司简介:Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403082324337a4ae1d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403082324337a4ae1d3&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1616},{"period":"1month","weight":-0.0359},{"period":"3month","weight":3.4062},{"period":"6month","weight":6.4074},{"period":"1year","weight":4.1475},{"period":"ytd","weight":3.4062}],"compareEarnings":[{"period":"1week","weight":0.0017},{"period":"1month","weight":0.0318},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.2236},{"period":"1year","weight":0.3033},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司,致力于开发新的,第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612,它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物,它在同药物中排列第一。公司的第二临床程序vk5211,可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂,或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.031825},{"month":2,"riseRate":0.555556,"avgChangeRate":0.264573},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020024},{"month":4,"riseRate":0.5,"avgChangeRate":0.003101},{"month":5,"riseRate":0.333333,"avgChangeRate":0.129034},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.009265},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.014001},{"month":8,"riseRate":0.444444,"avgChangeRate":0.019922},{"month":9,"riseRate":0.333333,"avgChangeRate":0.070513},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.002105},{"month":11,"riseRate":0.555556,"avgChangeRate":0.0115},{"month":12,"riseRate":0.666667,"avgChangeRate":0.206888}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}